Can I Take Vitamin B6 with Rapamycin (Sirolimus)?

The short answer: low-dose B6 is fine, high-dose B6 needs a second look

No published pharmacokinetic study has shown that vitamin B6 (pyridoxine) changes sirolimus blood levels or that sirolimus alters B6 absorption or metabolism in a clinically meaningful way. The concern is pharmacodynamic, not pharmacokinetic. Both high-dose B6 and sirolimus have been independently linked to peripheral nerve symptoms, so taking them together at elevated B6 doses raises the practical question of whether you could develop neuropathy faster, or make it harder for your clinician to figure out which agent is responsible.

For most women taking a standard multivitamin or a B-complex that stays below 50 mg of pyridoxine per day, the combination is unlikely to pose additional risk beyond what sirolimus alone carries. If your supplement contains 100 mg or more of B6 per dose, that changes the calculation.

What rapamycin actually does in the body

Rapamycin inhibits mTOR (mechanistic target of rapamycin), a kinase that regulates cell growth, protein synthesis, and autophagy. In transplant medicine, sirolimus is approved by the FDA to prevent organ rejection, typically at trough blood levels of 4 to 12 ng/mL for most kidney-transplant protocols. Off-label, clinicians prescribing it for longevity typically use much lower intermittent doses, often 1 to 6 mg once weekly, though no standardized longevity protocol has been validated in a large RCT.

MTOR inhibition also affects immune function broadly, which is relevant for women because immune activity shifts across the menstrual cycle, during pregnancy, and after menopause.

What vitamin B6 does and where its risk comes from

Pyridoxine is a water-soluble B vitamin essential for neurotransmitter synthesis, amino acid metabolism, and hemoglobin production. At food-equivalent intakes (1 to 3 mg/day), toxicity is not a concern. At supplement doses above 50 mg/day taken chronically, sensory peripheral neuropathy has been documented in the medical literature, with some case reports appearing at doses as low as 24 mg/day over long periods.

The tolerable upper intake level (UL) set by the National Institutes of Health is 100 mg/day for adults, but that figure is based on a no-observed-adverse-effect level, not a guarantee of safety for every individual. Women with pre-existing nerve conditions or those taking other neurotoxic medications should treat the UL as a ceiling, not a target.

Is there a direct drug-supplement interaction between rapamycin and B6?

The direct answer is: not a pharmacokinetic one. Sirolimus is metabolized primarily by CYP3A4 and P-glycoprotein, and pyridoxine does not meaningfully inhibit or induce either pathway at any dose a human would take. You will not find vitamin B6 on the list of CYP3A4 modulators, and no peer-reviewed study has reported a change in sirolimus trough levels attributable to B6 co-administration.

What does matter is the shared neurological territory.

The pharmacodynamic overlap to know about

Sirolimus and its analogue everolimus have been associated with peripheral neuropathy in case reports, though this is not among the most common side effects listed in the transplant prescribing information. The mechanism is thought to involve mTOR's role in Schwann-cell function and axonal maintenance, both of which depend on adequate myelination support. Separately, high-dose pyridoxine causes a predominantly sensory neuropathy by overwhelming the nerve's ability to process the active form, pyridoxal-5-phosphate, leading to accumulation of the precursor and direct dorsal-root-ganglion toxicity.

There is no human trial that has specifically studied whether the two together worsen neuropathy risk compared with either alone. This is an evidence gap you deserve to know about. What your clinician can do is monitor for early neuropathy symptoms, such as tingling in your feet or unsteady gait, and attribute them correctly if they appear.

Symptoms that should prompt a call to your prescriber

• Tingling, burning, or numbness starting in the feet or hands
• Difficulty with balance or walking in the dark
• Unusual sensitivity to light touch on the skin
• Muscle weakness in the lower legs

Any of these warrant a conversation, not just a Google search.

How dose matters for women specifically

Women's B6 requirements and metabolism differ from men's in ways that are not always reflected in generic supplement labeling. The Recommended Dietary Allowance (RDA) for B6 is 1.3 mg/day for women aged 19 to 50 and rises to 1.5 mg/day after age 51. Pregnancy increases the RDA to 1.9 mg/day. These numbers are achievable from food alone for most women eating a varied diet.

The problem is the supplement market. B-complex products marketed for energy, PMS relief, or stress commonly contain 50 to 100 mg of pyridoxine per capsule, a dose 30 to 70 times the RDA. Women in perimenopause are disproportionately targeted by these products, often without guidance on the upper limit.

Life-stage breakdown

Reproductive years (19 to 50). If you take oral contraceptives, your measured serum B6 may run slightly lower than in non-OCP users, which has historically been used to justify higher supplemental B6. The actual clinical evidence for B6 deficiency on modern low-dose OCPs is thin. A 2021 systematic review in Nutrients found inconsistent data on OCP-related B6 status changes and did not support routine high-dose supplementation. Keep your B6 supplement below 25 mg/day unless your clinician has measured a true deficiency.

Trying to conceive or pregnant. Rapamycin is FDA Pregnancy Category C, meaning animal studies have shown harm and there are no adequate human trials. See the dedicated section below.

Perimenopause. This is the life stage where the B6-plus-rapamycin combination is most likely to appear together. Some women explore off-label rapamycin for longevity or metabolic health during perimenopause, while simultaneously taking high-dose B-complex supplements for mood fluctuations or hot-flush symptom relief. If this describes you, check your B6 dose on the label before starting sirolimus, and aim to stay at or below 25 mg/day of supplemental pyridoxine.

Post-menopause. The RDA rises modestly to 1.5 mg/day, and post-menopausal women taking rapamycin for longevity are the group most likely to be on the drug long-term. Long-term monitoring for peripheral neuropathy is reasonable, and keeping a symptom diary is practical.

A simple dose-based decision framework

| Supplemental B6 dose per day | Action before starting sirolimus | |---|---| | <10 mg (food or low-dose multi) | No additional precaution needed | | 10 to 49 mg | Discuss with prescriber; document baseline neurological symptoms | | 50 to 100 mg | Reduce to <25 mg or have a specific clinical reason to continue | | >100 mg | Do not start sirolimus until B6 dose is addressed |

Pregnancy, lactation, and contraception: what every woman must know

This section is mandatory reading if you are pregnant, breastfeeding, or not using reliable contraception while taking sirolimus.

Pregnancy

Rapamycin (sirolimus) is FDA Pregnancy Category C. Animal studies in rats and rabbits have shown embryotoxicity and reduced fetal weights at doses below human therapeutic levels. There are no adequate, well-controlled studies in pregnant women. Because the animal data shows harm and the human data is essentially absent, sirolimus should not be used during pregnancy unless a transplant physician has determined that the benefit to the mother clearly outweighs the fetal risk.

For women taking rapamycin off-label for longevity, the calculus is straightforward: the drug should be stopped before attempting conception.

Vitamin B6 at the RDA level (1.9 mg/day during pregnancy) is safe and actually required for fetal neurodevelopment. High-dose B6 (above 100 mg/day) during pregnancy has not been established as safe in large human trials, though doses used clinically for hyperemesis gravidarum (10 to 25 mg several times daily) have a long safety record.

Lactation

Sirolimus has been detected in breast milk in animal studies. The prescribing information advises against breastfeeding during sirolimus therapy because of the potential for serious adverse reactions in the nursing infant, including immunosuppression. Human pharmacokinetic data on sirolimus transfer into breast milk is limited, which is itself a reason for caution.

Vitamin B6 transfers into breast milk and actually supports infant neurological development at normal dietary intakes. High-dose supplemental B6 during lactation is not recommended because the safety for the infant has not been well characterized at doses above 50 mg/day.

Contraception requirement

Because sirolimus carries embryotoxic risk, the prescribing information specifically recommends effective contraception before starting therapy, throughout treatment, and for 12 weeks after stopping sirolimus. This applies even if you are taking it off-label. Sirolimus may also affect the efficacy of hormonal contraceptives through CYP3A4 interactions (sirolimus itself is a CYP3A4 substrate, and some progestins share metabolic pathways), so discuss your contraception method with your prescriber.

Women-specific conditions where both rapamycin and B6 are relevant

PCOS

Women with polycystic ovary syndrome have heightened interest in mTOR biology because mTOR signaling is dysregulated in PCOS-related insulin resistance. Some researchers have proposed sirolimus as a potential tool in PCOS management, though no RCT has established efficacy or safety for this indication in women with PCOS. Separately, inositol (sometimes confused with B vitamins) and B6 are both marketed to women with PCOS for insulin sensitivity, though the evidence base for B6 specifically in PCOS is not strong.

Autoimmune conditions common in women

Lupus, rheumatoid arthritis, and inflammatory bowel disease are more prevalent in women, and sirolimus has been studied in some of these contexts. Women with these conditions may already be taking high-dose B-vitamins as part of complex supplement regimens. This increases the likelihood of the B6-sirolimus co-exposure scenario described throughout this article.

Peripheral neuropathy from prior chemotherapy

Women who have received neurotoxic chemotherapy (platinum agents, taxanes) and who are now exploring longevity or anti-aging protocols with sirolimus should be especially cautious about additional neurological risk from high-dose B6. Their baseline neuropathy makes new symptoms harder to attribute and harder to tolerate.

Who this is right for and who should pause

Good candidates for low-dose B6 plus sirolimus

• Women taking a standard multivitamin with 1 to 5 mg of B6 per serving
• Women whose dietary B6 intake from food covers their RDA without supplementation
• Post-menopausal women on low-dose intermittent sirolimus who do not have pre-existing neuropathy and are willing to do periodic symptom checks

Women who should reconsider or adjust

• Anyone taking a B-complex with 50 mg or more of B6 per dose
• Women with pre-existing peripheral neuropathy from any cause, including diabetes, chemotherapy, or alcohol use
• Women who are pregnant, trying to conceive, or breastfeeding (sirolimus is the disqualifying factor here, not B6)
• Women with significant renal impairment, since sirolimus accumulates and B6's metabolic products are renally cleared
• Women on strong CYP3A4 inhibitors such as fluconazole or clarithromycin, since sirolimus levels can spike regardless of B6 status

What to monitor and when

Your prescriber should check sirolimus trough levels (target varies by indication; transplant protocols generally aim for 4 to 12 ng/mL, while longevity prescribers may target 3 to 8 ng/mL once weekly dosing) at baseline, after any dose change, and after starting or stopping any drug or supplement that touches CYP3A4.

For B6, routine serum measurement is not necessary at dietary doses. If you are taking more than 25 mg/day of supplemental pyridoxine and experience any neurological symptom, your clinician can order a plasma pyridoxal-5-phosphate level. A value above 200 nmol/L in the context of neuropathy symptoms warrants dose reduction.

A practical monitoring schedule:

• Baseline. Neurological symptom review, B6 supplement dose confirmed, sirolimus trough drawn.
• 4 to 8 weeks after starting. Symptom check for tingling, balance issues, hand or foot numbness.
• Every 3 to 6 months ongoing. Symptom diary review, trough level per prescriber protocol, metabolic panel.

The evidence gap women deserve to know about

Most of the safety and efficacy data for sirolimus comes from kidney-transplant populations, which have historically skewed male. The off-label longevity use of rapamycin in women is growing, driven partly by interest in the ITP (Interventions Testing Program) mouse studies showing lifespan extension, where female mice showed a larger survival benefit than male mice. Translating that finding to human women requires enormous caution. No large RCT has enrolled women to test longevity dosing regimens, and pharmacokinetic data in women across reproductive life stages is almost entirely absent.

The B6 interaction specifically has not been studied in any clinical trial population, male or female. Every recommendation in this article is based on the known independent pharmacology of each agent. That is the honest state of the evidence.

Practical steps before combining B6 and rapamycin

1. Read your supplement label. Confirm the milligrams of pyridoxine (B6) per serving, not just "B-complex."
2. Aim for a total supplemental B6 intake below 25 mg/day while taking sirolimus.
3. Tell your prescribing clinician every supplement you take, including the dose.
4. Get a baseline neurological assessment if you have any prior neuropathy history.
5. Keep a symptom diary for the first three months and note any tingling, numbness, or balance changes.
6. If you are in perimenopause and taking B-complex for mood support, ask your clinician whether magnesium glycinate or a lower-dose B-complex might meet your needs with less B6.
7. Do not take sirolimus if you are pregnant or planning pregnancy without a specialist consultation.

Your rapamycin prescriber should be the person coordinating your full medication and supplement list, not an algorithm or a supplement brand website.